MX348957B - Derivados de imidazol azabiciclicos sustituidos utiles como moduladores del receptor del canal 8 (subfamilia melastatina) del potencial de receptor transitorio. - Google Patents

Derivados de imidazol azabiciclicos sustituidos utiles como moduladores del receptor del canal 8 (subfamilia melastatina) del potencial de receptor transitorio.

Info

Publication number
MX348957B
MX348957B MX2016000495A MX2016000495A MX348957B MX 348957 B MX348957 B MX 348957B MX 2016000495 A MX2016000495 A MX 2016000495A MX 2016000495 A MX2016000495 A MX 2016000495A MX 348957 B MX348957 B MX 348957B
Authority
MX
Mexico
Prior art keywords
inflammatory
imidazole derivatives
receptor modulators
derivatives useful
substituted aza
Prior art date
Application number
MX2016000495A
Other languages
English (en)
Inventor
Mark R Player
Jinsheng Chen
William Parsons
Raul CALVO
Sanath Meegalla
Daniel Parks
Scott Ballentine
Shawn Branum
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX348957B publication Critical patent/MX348957B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16—Halogenated acetic acids
    • C07C53/18—Halogenated acetic acids containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención está dirigida a derivados azabicíclicos sustituidos de imidazol, composiciones farmacéuticas que los contienen y su uso en el tratamiento de trastornos y condiciones modulados por el TRP M8, que incluyen, por ejemplo, dolor inflamatorio, hiperalgesia inflamatoria, condición de hipersensibilidad inflamatoria, dolor neuropático, alodinia neuropática al frío, hiperalgesia inflamatoria somática, hiperalgesia inflamatoria visceral, enfermedad cardiovascular agravada por el frío y enfermedad pulmonar agravada por el frío.
MX2016000495A 2010-03-05 2011-03-03 Derivados de imidazol azabiciclicos sustituidos utiles como moduladores del receptor del canal 8 (subfamilia melastatina) del potencial de receptor transitorio. MX348957B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31087010P 2010-03-05 2010-03-05
PCT/US2011/026974 WO2011109587A1 (en) 2010-03-05 2011-03-03 Substituted aza-bicyclic imidazole derivatives useful as trpm8 receptor modulators

Publications (1)

Publication Number Publication Date
MX348957B true MX348957B (es) 2017-07-04

Family

ID=43875233

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016000495A MX348957B (es) 2010-03-05 2011-03-03 Derivados de imidazol azabiciclicos sustituidos utiles como moduladores del receptor del canal 8 (subfamilia melastatina) del potencial de receptor transitorio.
MX2015000028A MX336354B (es) 2010-03-05 2011-03-03 Derivados de imidazol azabiciclicos sustituidos utiles como moduladores del receptor del canal 8 (subfamilia melastatina) del potencial de receptor transitorio.
MX2012010270A MX2012010270A (es) 2010-03-05 2011-03-03 Derivados de imidazol azabicíclicos sustituidos útiles como moduladores del receptor del canal 8 (subfamilia melastatina) del potencial de receptor transitorio.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2015000028A MX336354B (es) 2010-03-05 2011-03-03 Derivados de imidazol azabiciclicos sustituidos utiles como moduladores del receptor del canal 8 (subfamilia melastatina) del potencial de receptor transitorio.
MX2012010270A MX2012010270A (es) 2010-03-05 2011-03-03 Derivados de imidazol azabicíclicos sustituidos útiles como moduladores del receptor del canal 8 (subfamilia melastatina) del potencial de receptor transitorio.

Country Status (16)

Country Link
US (4) US8680098B2 (es)
EP (1) EP2542552B1 (es)
JP (1) JP5782054B2 (es)
KR (1) KR101667277B1 (es)
CN (1) CN102884063B (es)
AR (1) AR080388A1 (es)
AU (1) AU2011223566B2 (es)
BR (1) BR112012022369A2 (es)
CA (1) CA2791715C (es)
DK (1) DK2542552T3 (es)
ES (1) ES2654399T3 (es)
MX (3) MX348957B (es)
NZ (1) NZ601998A (es)
TW (1) TWI567071B (es)
UY (1) UY33264A (es)
WO (1) WO2011109587A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8680098B2 (en) * 2010-03-05 2014-03-25 Janssen Pharmaceutica, Nv Substituted aza-bicyclic imidazole derivatives useful as TRPM8 receptor modulators
GB2573597B8 (en) 2015-06-22 2025-08-06 Time Machine Capital Ltd Auditory augmentation system
JP6454418B2 (ja) * 2015-06-23 2019-01-16 キッセイ薬品工業株式会社 ピラゾール誘導体、またはその薬理学的に許容される塩
CN117088871A (zh) * 2018-11-30 2023-11-21 四川科伦博泰生物医药股份有限公司 并环化合物、其制备方法及用途
CN110638807A (zh) * 2019-08-23 2020-01-03 陈明英 局部镇痛用药物组合物、其制备方法及其应用
US12455295B2 (en) 2023-08-17 2025-10-28 Rosemount Aerospace Inc. Conformal multi-function air-data probes

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60260579A (ja) 1984-01-13 1985-12-23 Yoshitomi Pharmaceut Ind Ltd プリン誘導体
US6566367B2 (en) * 2000-12-12 2003-05-20 Pfizer Inc. Spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines
EP1460067A4 (en) * 2001-11-26 2005-12-07 Takeda Pharmaceutical BICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE
US7582761B2 (en) 2002-10-17 2009-09-01 Amgen Inc. Vanilloid receptor ligands and their use in treatments
JP2007513105A (ja) 2003-12-02 2007-05-24 ユ セ ベ ソシエテ アノニム イミダゾール誘導体、その製法及び使用
AR050630A1 (es) * 2004-09-09 2006-11-08 Solvay Pharm Bv DERIVADOS DE 6- TRIFLUOROMETIL PURINA 2- SUSTITUIDA CON ACTIVIDAD ANTAGONISTA DE ADENOSINA-A3. PROCESOS DE OBTENCIoN Y COMPOSICIONES FARMACÉUTICAS.
GB0508472D0 (en) * 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
EP1891048A1 (en) 2005-06-11 2008-02-27 Vernalis (R&D) Limited Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders
HRP20151078T1 (hr) 2006-03-22 2015-11-20 F. Hoffmann - La Roche Ag Pirazoli kao 11-beta-hsd-1
US20080139608A1 (en) 2006-12-06 2008-06-12 Universiteit Leiden 2,6,8, Trisubstituted 1-deazapurines and their different uses
AU2008253311A1 (en) 2007-05-18 2008-11-27 Bayer Schering Pharma Aktiengesellshaft Inhibitors of hypoxia inducible factor (HIF) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
PT2242759E (pt) 2008-02-06 2012-12-17 Astrazeneca Ab Compostos
PL2294066T3 (pl) 2008-04-28 2015-02-27 Janssen Pharmaceutica Nv Benzimidazole jako inhibitory hydroksylazy prolilowej
US8680098B2 (en) * 2010-03-05 2014-03-25 Janssen Pharmaceutica, Nv Substituted aza-bicyclic imidazole derivatives useful as TRPM8 receptor modulators

Also Published As

Publication number Publication date
MX2012010270A (es) 2013-04-24
US20110218197A1 (en) 2011-09-08
MX336354B (es) 2016-01-14
ES2654399T3 (es) 2018-02-13
UY33264A (es) 2011-09-30
CA2791715C (en) 2018-05-15
WO2011109587A1 (en) 2011-09-09
KR20130018750A (ko) 2013-02-25
AR080388A1 (es) 2012-04-04
US9023846B2 (en) 2015-05-05
US20150158875A1 (en) 2015-06-11
CN102884063B (zh) 2015-11-25
AU2011223566A1 (en) 2012-09-20
TWI567071B (zh) 2017-01-21
AU2011223566B2 (en) 2015-05-21
EP2542552A1 (en) 2013-01-09
DK2542552T3 (en) 2017-12-11
US8680098B2 (en) 2014-03-25
NZ601998A (en) 2014-03-28
CA2791715A1 (en) 2011-09-09
CN102884063A (zh) 2013-01-16
BR112012022369A2 (pt) 2017-08-29
EP2542552B1 (en) 2017-11-15
JP5782054B2 (ja) 2015-09-24
US9409915B2 (en) 2016-08-09
KR101667277B1 (ko) 2016-10-18
TW201144309A (en) 2011-12-16
JP2013521306A (ja) 2013-06-10
US20160304518A1 (en) 2016-10-20
US20140155395A1 (en) 2014-06-05
US9718820B2 (en) 2017-08-01

Similar Documents

Publication Publication Date Title
MX336354B (es) Derivados de imidazol azabiciclicos sustituidos utiles como moduladores del receptor del canal 8 (subfamilia melastatina) del potencial de receptor transitorio.
MX351368B (es) Compuestos heteroarilo y metodos para utilizarlos.
PH12013500145B1 (en) Agonists of gpr40
GEP20156266B (en) Spiroheterocyclic n-oxypiperidines as pesticides
CA2871471C (en) Dna-pk inhibitors
EP3699176A3 (en) Antiviral compounds
WO2011082400A3 (en) Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
ZA201803013B (en) Use of pydiflumetofen for the reduction of mycotoxin contamination in plants
WO2008152099A3 (en) Aryl/hetarylamides as modulators of the ep2 receptor
PH12014502141A1 (en) New indanyloxydihydrobenzofuranylacetic acid derivatives and their use as gpr40 receptor agonists
NZ743274A (en) Substituted tricyclic compounds as fgfr inhibitors
PH12013501290A1 (en) 2-amino-4-arylthiazole compounds as trpa1 antagonists
MX2012012530A (es) Derivados de n1-sulfonil-5-fluorpirimidinona.
EP2576578A4 (en) POLYMORPHES OF 2'-O-FUCOSYLLACTOSE AND MANUFACTURE THEREOF
NZ705213A (en) C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
MX348451B (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparación y su uso como antagonistas p2y12.
EA201490152A1 (ru) Антагонисты trpm8 и их применение при лечении
MX2020006235A (es) Nuevos derivados de benzamida como moduladores de ppar-gamma.
WO2011123678A3 (en) Substituted benzo-pyrido-triazolo-diazepine compounds
WO2011151436A3 (en) Azepin-derivatives as derivatives as g- protein coupled receptor (gpr43) agonists
IN2015DN00345A (es)
MX2013013436A (es) Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos.
WO2012061342A3 (en) Substituted benzo-imidazo-pyrido-diazepine compounds
IN2014KN00849A (es)
WO2011127482A3 (en) Modulation of histone deacetylases for the treatment of metabolic disease, methods and compositions related thereto